In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBE Therapeutics AG

http://www.nbe-therapeutics.com

Latest From NBE Therapeutics AG

136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure

The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.

Companies Business Strategies

Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds

Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.

Emerging Company Profile Clinical Trials

Boehringer Reflects On Resilience Of Older Therapies

The German group is investing heavily in R&D and the continued strong performance of products like Spiriva and Pradaxa is helping to pay for future innovation.

Sales & Earnings Commercial

Boehringer Ingelheim Backs R&D With Big Bucks

Jardiance and Ofev are growing strongly but the German drugmaker is also confident its pipeline will bear fruit, boosted by a rising research budget that represents almost 23% of sales.

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register